Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease portal hypertension
Comorbidity C0023895|liver disease
Sentences 39
PubMedID- 24171010 The authors concluded that patients who carry the z allele are at greater risk (or, ≈ 5) of developing severe liver disease with portal hypertension (31).
PubMedID- 21196656 Esophageal varices develop as a consequence of portal hypertension in patients with chronic liver disease and are present in approximately 50% of patients with cirrhosis of the liver.
PubMedID- 25147571 The most common cause of colonic varices is portal hypertension associated with liver disease or secondary to pancreatic conditions, like chronic pancreatitis or malignancies.
PubMedID- 25590846 Furthermore, to exclude the effect of cardiovascular factors, patients with confirmed cardiovascular diseases or taking any agents affecting qtc interval before the establishment of achblf were excluded, such as β-blockers, even if it is recommended in patients with portal hypertension associated with chronic liver diseases.
PubMedID- 24613858 Purpose of review: cirrhosis is the result of the progression of necroinflammatory liver diseases leading to fibrosis, portal hypertension, and a catabolic state, which might cause muscle wasting or sarcopenia.
PubMedID- 22270437 Background: cirrhotic liver disease commonly is complicated by portal hypertension, and the resultant porto-systemic shunts are an important cause of morbidity and mortality in cirrhotic patients.
PubMedID- 25374709 Hepatic myelopathy or porto-systemic myelopathy is a rare neurological complication of chronic liver disease with portal hypertension, usually associated with porto-systemic shunting, and presents as pure motor spastic paraparesis without sensory or sphincter involvement.
PubMedID- 22610002 Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.
PubMedID- 22190914 Reported that the accuracy of their string ece for diagnosing ev and portal hypertension in patients with chronic liver disease was excellent [23].
PubMedID- 21712949 Further evaluation showed that he had chronic liver disease with portal hypertension and was hepatitis b surface antigen-positive, indicating hepatitis b infection.
PubMedID- 24782928 Dyspnea in a patient with liver dysfunction usually makes one suspects hepatopulmonary syndrome, portopulmonary hypertension, cardiomyopathy, hepatic hydrothorax, ascites, or anemia, whereas ascites itself is a hallmark of liver disease complicated by portal hypertension.
PubMedID- 25667596 Cirrhosis is scarring of the liver and also is the final stage of many chronic liver diseases, leading to portal hypertension and end-stage liver disease [1].
PubMedID- 22973991 Objectives: transient elastography (te), as a non-invasive method, has been studied for evaluation of portal hypertension in patients with chronic liver diseases (cld) with variable results.
PubMedID- 22689731 Here, the authors discuss a case of pancreatic ascites developing in the setting of alcoholic liver disease with portal hypertension.
PubMedID- 22986694 Purpose: cystic-fibrosis-associated liver disease (cfld) may lead to portal hypertension (pht) and cirrhosis.
PubMedID- 21055685 Hepatic granulomas may be manifested clinically by elevated levels of serum alkaline phosphatase and g-glutamyltransferase enzymes, damage to specific structures (eg, intrahepatic bile ducts in primary biliary cirrhosis), or infrequently, progressive liver disease with portal hypertension and cirrhosis (eg, sarcoidosis).
PubMedID- 21229317 Unfortunately, the patient had progressive biliary cirrhosis to end-stage liver disease complicated with portal hypertension for which she underwent successful orthotopic liver transplant at 7 years of age.
PubMedID- 24142390 The insertion of a transjugular intrahepatic portosystemic shunt (tips) is a minimally invasive procedure used to relieve the signs and symptoms of portal hypertension in patients with liver disease.
PubMedID- 26201624 Hepatic hydrothorax (hh) is an infrequent but a well-known complication of portal hypertension in patients with end-stage liver disease.
PubMedID- 22662598 Clinical application of transient elastography in prediction of portal hypertension related complication in patients with chronic liver diseases.
PubMedID- 21813019 To our knowledge, ha is the only serum marker that has been confirmed as an independent predictor of portal hypertension in patients with liver disease [20].
PubMedID- 20065573 Background/aim: esophageal varices (evs) are a serious consequence of portal hypertension in patients with liver diseases.
PubMedID- 21389796 Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis.
PubMedID- 24820314 Hps is a significant complication of portal hypertension in children with chronic liver disease and is an established indication for lt.
PubMedID- 24759352 The patient was diagnosed as having chronic liver disease with portal hypertension, with etiology probably related to non-alcoholic steatohepatitis (nash), with present decompensation due to drug-induced liver injury and sbp due to s. typhimurium.
PubMedID- 23123767 Measuring spp using ultrasound is most simple and minimally invasive, and it might be useful for evaluating portal hypertension in dogs with liver diseases.
PubMedID- 24616589 Relationship between tetrahydrobiopterin and portal hypertension in patients with chronic liver disease.
PubMedID- 20453271 A novel mutation g-to-a at position 333 in exon v was found in two siblings having positive immunohistochemistry for aat on liver biopsy, both of whom had significant liver disease with portal hypertension.
PubMedID- 21685145 Background: a group of non-cirrhotic chronic liver diseases, all with sustained portal hypertension and clinically mistaken as cirrhosis, have been described under various names, apparently because of differences in pathological features.
PubMedID- 22586877 She also had diagnoses of chronic liver disease with cirrhotic changes, portal hypertension, and grade iv manageesophageal varices with hepatosplenomegaly.
PubMedID- 21932390 Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib.
PubMedID- 23812037 Therefore, hscs can contribute to portal hypertension in patients with chronic liver disease (cld).
PubMedID- 24457056 Aitp has been classified either as a primary autoimmune disorder or as secondary to a number of underlying conditions such as lymphoproliferative disorders, myelodysplasia, autoimmune collagen vascular diseases (e.g., systemic lupus erythematosus, antiphospholipid antibody syndrome) liver disease with portal hypertension, drugs or viral infection.
PubMedID- 24771990 Chronic liver disease, especially with associated portal hypertension, has also been linked to the presence of gi angioectasias and, as reported by some authors, they could be reversed after transjugular intrahepatic portosystemic shunt [34, 38, 39].
PubMedID- 24340101 Two weeks after the surgery [28], the animal model of obstructive liver disease with portal hypertension was developed.
PubMedID- 22567478 Significant morbidity is seen in those patients who develop complications such as end-stage renal diseases, chronic liver diseases with portal hypertension, and cancers associated with schistosomiasis [1–3].
PubMedID- 24796378 Aim: liver fibrosis occurs as a result of several chronic liver diseases and leads to portal hypertension, cirrhosis and liver failure, often requiring liver transplantation.
PubMedID- 26117383 Severe mdr3 deficiency typically presents during the first year of life or early childhood, often progressing to chronic liver disease with cirrhosis and portal hypertension, requiring liver transplantation.
PubMedID- PMC3239438 The patient was suffering from advanced liver disease with portal hypertension and multiple current inter abdominal abscesses.

Page: 1